Bristol Myers Squibb gets EC nod for expanded use of Breyanzi
https://seekingalpha.com/news/4420725-bristol-myers-squibb-gets-ec-nod-for-expanded-use-of-breyanzi?source=feed_sector_healthcare
Mar 14, 2025 -
0
Ecopetrol S.A. (EC) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4675412-ecopetrol-s-ec-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Mar 01, 2024 - Ecopetrol S.A. (NYSE:NYSE:EC) Q4 2023 Earnings Call Transcript March 1, 2024 9:00 AM ETCompany ParticipantsRicardo Roa - CEOAlberto Consuegra - COODavid...
0
Pfizer hemophilia B gene therapy Durveqtix wins EC authorization
https://seekingalpha.com/news/4128465-pfizer-hemophilia-b-gene-therapy-durveqtix-wins-ec-authorization?source=feed_sector_healthcare
Jul 25, 2024 - Pfizer's gene therapy Durveqtix receives conditional marketing authorization from the European Commission for hemophilia B. Read more here.
0
Ecopetrol S.A. (EC) Q2 2024 Earnings Call Transcript
https://seekingalpha.com/article/4715380-ecopetrol-s-ec-q2-2024-earnings-call-transcript?source=feed_sector_transcripts
Aug 17, 2024 - Ecopetrol S.A. (NYSE:NYSE:EC) Q2 2024 Earnings Conference Call August 14, 2024 10:00 AM ETCompany ParticipantsRicardo Roa - Chief Executive OfficerRafael...
0
Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up
https://www.zacks.com/stock/news/2197568/blueprint-bpmc-gets-ec-nod-for-ayvakit-expanded-use-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197568
Dec 13, 2023 - Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.
0
Here's Why it is Worth Investing in Sunoco (SUN) Stock Now
https://www.zacks.com/stock/news/2201564/here-s-why-it-is-worth-investing-in-sunoco-sun-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2201564
Dec 22, 2023 - Sunoco (SUN) raises its 2023 EBITDA guidance to above $935 million, banking on its continued strong performance.
0
Ecopetrol (EC) Gears Up for Q4 Earnings: What's in Store?
https://www.zacks.com/stock/news/2231076/ecopetrol-ec-gears-up-for-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2231076
Feb 23, 2024 - Lower commodity prices are likely to have hurt Ecopetrol's (EC) Q4 earnings to some extent.
0
Ecopetrol (EC) Wins Dispute, Awarded McDermott Share Capital
https://www.zacks.com/stock/news/2246882/ecopetrol-ec-wins-dispute-awarded-mcdermott-share-capital?cid=CS-ZC-FT-analyst_blog|company_news_-_energy_sector-2246882
Mar 27, 2024 - Ecopetrol's (EC) Reficar receives the 19.9% convertible preferred shares of McDermott International under a financial restructuring plan proposed by its subsidiary, CB&I N.V.
0
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
https://www.zacks.com/stock/news/2249839/bristol-myers-bmy-wins-ec-nod-for-reblozyl-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249839
Apr 03, 2024 - Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
0
Here's Why Hold Strategy is Apt for EOG Resources (EOG) Stock
https://www.zacks.com/stock/news/2280217/here-s-why-hold-strategy-is-apt-for-eog-resources-eog-stock?cid=CS-ZC-FT-analyst_blog|rank_focused-2280217
May 28, 2024 - EOG Resources' (EOG) strategic positioning in the U.S. oil markets, with diversified sales to domestic refiners and export-linked capacity, provides a competitive advantage.
0
Page 1>